- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
World High Life PLC Announces LH Botanicals Increases Capacity to Meet Demand
Wholly Owned Subsidiary Adds New Technology and Manufacturing Machines, Expanding Product Lines Offered at Wholesale
World High Life Plc (AQSE:LIFE)(OTCQB:WRHLF) is pleased to announce that its wholly owned subsidiary, Love Hemp Ltd (“Love Hemp”), has increased capacity for its LH Botanicals business with new machinery and technology to meet growing demand.
Established by the founders of Love Hemp, Tony Calamita and Thomas Rowland, the London-headquartered company, LH Botanicals provides a complete range of CBD products for wholesale, bulk and white label, with all products certified THC-free in customisable bottle sizes, concentrations, and flavours.
The Company has found that demand for LH Botanicals’ CBD products is continuing to rise and, as noted within the Company’s announcement on 7 May 2020, the Company has responded by increasing production capacity by acquiring a new capsule machine and a new bath bomb machine to extend its product offerings in an attempt to increase market share further. In addition, LH Botanicals has invested in advanced in-house technology that can test for the widest range of cannabinoids as standard.
LH Botanicals Highlights
- LH Botanicals’ bulk CBD products are available as CBD rich oils, isolate crystals, water soluble powders, body salves, liquid terpenes, flavoured isolate e-liquids, broad spectrum unflavoured e-liquids, vegan jelly domes, gummy bears, and soft gel capsules
- LH Botanicals has expanded their product offering with the addition of a bath bomb machine capable of producing 5,000 bath bombs per day
- LH Botanicals has also responded to an increase in customer demand for capsules with the acquisition of an additional capsule machine capable of producing 100,000 capsules daily
Love Hemp CEO, Tony Calamita commented: “We are proud to offer exceptional levels of service and the most competitive pricing when it comes to wholesale CBD. Our broad spectrum Phyto cannabinoid-rich industrial hemp is naturally developed and grown in America, and an advanced cloning programme is used to ensure the consistency of the genetic strains to create a safe and regulated product with excellent characteristics. The acquisition of a bath bomb and additional capsule machine is testament to our continued success, and the trust we have built as a brand.”
For further information please contact:
David Stadnyk
Founder & CEO
World High Life PLC
North America toll-free, 1 (888) 616-WRHLF (9745)
+44 (0) 7926 397 675
info@worldhighlife.uk
AQSE Corporate Adviser
Mark Anwyl/Allie Feuerlein
Peterhouse Capital Limited
+44 (0) 20 7469 0930
ma@peterhousecap.com
af@peterhousecap.com
Financial PR
Camilla Horsfall/Megan Ray
Blytheweigh
+44 (0) 20 7138 3224
Camilla.horsfall@blytheweigh.com
Megan.Ray@blytheweigh.com
For more information on World High Life please visit: www.worldhighlife.uk
Market Abuse Regulation (MAR) Disclosure
The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014. Upon the publication of this announcement via a Regulatory Information Service, this inside information is now considered to be in the public domain.
Cautionary Note Regarding Forward Looking Information
We seek safe harbour. Some statements contained in this news release are “forward looking information” within the meaning of securities laws. Forward looking information include, but are not limited to, statements regarding the use of proceeds of the non-brokered private placement and payment of the debt settlements. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “plans”, “expects”, “is expected”, “budget”, “scheduled”, “estimates”, “forecasts”, “intends”, “anticipates”, “believes” or variations of such words and phrases (including negative or grammatical variations) or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved” or the negative connotation thereof. Investors are cautioned that forward-looking information is inherently uncertain and involves risks, assumptions and uncertainties that could cause actual results to differ materially. There can be no assurance that future developments affecting the Company will be those anticipated by management. The forward-looking information contained in this press release constitutes management’s current estimates, as of the date of this press release, with respect to the matters covered thereby. We expect that these estimates will change as new information is received. We do not undertake to update any estimate at any particular time or in response to any particular event, except as required by law.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.